Chinese regulators are investigating the quality of domestic generic drugs after a rare public backlash against a cost-cutting campaign that prioritised their use in the national healthcare system but has led to doctors complaining about their effectiveness.
manbetx3.0 监管机构正在调查国产仿制药的质量，起因是一项在国家医疗保健体系中优先使用此类药物的节省成本运动罕见地遭到了公众的强烈反对，一些医生抱怨国产仿制药的疗效。
您已阅读5%（336字），剩余95%（5783字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。